Karius Test®

A liquid biopsy for infectious diseases designed to help solve the diagnostic puzzle

400+

Hospitals

200+

Cancer Centers

100+

Transplant Centers

A Rapid Liquid Biopsy for Infectious diseases

The Karius Test utilizes a single blood sample to rapidly and non-invasively detect over 1000 pathogens associated with deep-seated and difficult-to-diagnose systemic infections. The Karius Test may help clinicians avoid many invasive, low-yield, and sequential diagnostic tests that can delay treatment for vulnerable hospitalized patients.

Clinical Care

The Karius Test is designed to help physicians diagnose infectious in immunocompromised patients. The main diagnostic applications of the Karius Test include: pneumonia, febrile neutropenia, endocarditis, invasive fungal infections, and fever of unknown origin.

Lab Services

The Karius Test provides you and your clinical team with the ability to use asingle blood draw to rapidly detect more than 1000
pathogens.

A Novel Liquid Biopsy

See how the Karius Test can provide clinicians with clear diagnostic insight

A Rapid Liquid Biopsy for Infectious Disease

The Karius Test is a liquid biopsy that can non-invasively and rapidly detect over 1000 pathogens causing both deep-seated and bloodstream infections from a single blood sample.

The Karius Test may help clinicians avoid invasive, low-yield, and sequential diagnostic tests that can delay treatment for vulnerable hospitalized patients.

Clinical Care

The main clinical application for the Karius Test is to help physicians diagnose infections in immunocompromised patients. The test helps diagnose pneumonia, invasive fungal infections, culture-negative endocarditis, opportunistic infections, and infectious causes of neutropenic fever and fever of unknown origin.

Lab Services

The Karius Test enables laboratories to offer clinicians the ability to rapidly detect over 1000 clinically relevant pathogens with a single blood draw.

Improving the diagnosis of life-threatening infections

The Karius Test has demonstrated higher diagnostic yield than the standard of care diagnostic tests in multiple studies.

Karius Test diagnostic yield

71%-92%

SOC diagnostic yield

7%-79%

USE CASE

Febrile neutropenia

55 adult patients with leukemia

KARIUS YIELD

85%

SOC YIELD

42%

Benamu E et al. Clin Infect Dis. Published online April 19, 2021. Epub ahead of print.

USE CASE

Prolonged/persistent fever, or imaging suspicious of infection

31 adult patients with hematologic malignancy +/-BMT

KARIUS YIELD

80%

SOC YIELD

35%

Yu J et al. Transplant Cell Ther. Published online February 26, 2021. Epub ahead of print.

USE CASE

Focal/systemic infections

79 pediatric patients (76% immunocompromised

KARIUS YIELD

92%

(63% invasive)

SOC YIELD

79%

(48% invasive)

Rosoff J et al. Open Forum Infect Dis. 2019;6(8)

USE CASE

Febrile neutropenia, pneumonia, or intra-abdominal infection

10 adults with chemotherapy or transplant

KARIUS YIELD

80%

SOC YIELD

60%

Camargo JF et al. F1000Res. 2019 Jul 26;8:1194

USE CASE

Invasive infections / FUO / Febrile neutropenia / culture-negative endocarditis

167 adult patients (36% immunocompromised)​

KARIUS YIELD

71%

SOC YIELD

7% (Blood Culture only)

Francisco, D., et al. Antimicrobial Stewardship & Healthcare Epidemiology, 3(1), E31.

USE CASE

Focal/systemic infections (Retrospective analysis of use)​

110 Pediatric patients​

KARIUS YIELD

74%

SOC YIELD

53%

Wilke J et al. BMC Infectious Diseases. 2021;21:552

USE CASE

Complicated community-acquired pneumonia​

46 pediatric patients

KARIUS YIELD

89%

SOC YIELD

26%

Dworsky ZD, et al. Hosp Pediatr. 2022 Mar 2:e2021006361

USE CASE

Infective endocarditis

10 pediatric patients​

KARIUS YIELD

80%

SOC YIELD

30% (Blood Culture) / ​50% (All)​

To RK et al. Pediatr Infect Dis J. 2021;40(5):486-488​

Designed to improve the diagnosis and management of life-threatening infections

Speeding up diagnosis of infections

The Karius Test results typically report the next day after sample receipt, compared with standard methods which can take days to weeks to yield results.5,6,8

Optimizing antimicrobial treatment

Karius Test pathogen identification and the addition of genotypic bacterial antimicrobial resistance (AMR) detection may help clinicians to optimize antimicrobial treatment.3,4

Reducing the need for invasive procedures

The Karius Test requires a single blood draw to reveal information-rich, microbial cell-free DNA, potentially avoiding invasive diagnostic procedures.1,2

One test, multiple diagnostic applications.

Invasive Fungal Infections
Pneumonia
Febrile Neutropenia
Endocarditis
Fever of Unknown Origin

Additional Resources

Testing Process

From blood sample to report, the Karius Test Process typically offers next day turnaround service.

Clinical and Analytical Validation

Multiple published studies describe the analytical validation and clinical evidence of the Karius Test.

Frequently Asked Questions

From clinical situations to sample collection to interpretation of results, find more specific information about Karius and Karius Test.

Ordering the Karius Test

The Karius Test is a send-out test that can be ordered by hospital clinicians. The patient's blood sample is collected at the hospital and shipped to the Karius laboratory overnight.

The kit includes:

  • Plasma preparation tube
  • Shipping materials
  • FedEx® Pak with preprinted label to Karius

References

  1. Foong et al. Open Forum Infectious Diseases. Vol. 9 Issue 12, December 2022, ofc652;
  2. Shishido et al. BMC Infectious Diseases (2022) 22:372;
  3. Francisco, D., et al. Antimicrobial Stewardship & Healthcare Epidemiology, 3(1), E31 ;
  4. Yu J et al. Transplant Cell Ther. Published online February 26, 2021.;
  5. Rossoff J et al. Open Forum Infect Dis. 2019;6(8).;
  6. Tabak YP et al. J Clin Microbiol. 2018;56(12). ;
  7. Bosshard PP. Mycoses. 2011;54(5):e539-545. ;
  8. Benamu E, et al.,Clin Infect Dis. 2021 Apr19:ciab324.